GlassScriptPhysician profile
Sunil K Dwivedi
NPI 1003854076
$7,016.40
in general payments reported to CMS, 2019-2025
30 companies · $2,582 in 2025
The $2,582 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $81.05 · 2021: $511 · 2022: $916 · 2023: $1,044 · 2024: $1,700 · 2025: $2,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,228 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.98 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,335.63 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,463.08 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $740.77 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $491.15 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $300.46 | 2020-2025 | Livdelzi |
| Ipsen Biopharmaceuticals, INC | $235.05 | 2024-2025 | Iqirvo |
| Pfizer INC. | $170.83 | 2019-2025 | |
| Qol Medical, LLC | $160.13 | 2023-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $150.88 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $149.36 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $122.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $102.18 | 2024-2025 | Omvoh |
| Celgene Corporation | $97.35 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $75.62 | 2021-2023 | |
| Cook Medical LLC | $42.86 | 2025 | Hemospray |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $40.57 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $39.21 | 2024 | |
| Ironwood Pharmaceuticals, INC | $39.10 | 2023-2024 | Linzess |
| Ardelyx, INC. | $34.27 | 2022-2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $32.78 | 2024 | Dificid |
| Evoke Pharma, INC. | $27.50 | 2021-2025 | |
| Ucb, INC. | $27.50 | 2019-2020 | |
| Redhill Biopharma INC. | $27.00 | 2022 | |
| Allergan, INC. | $24.01 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $19.67 | 2024-2025 | Forceps |
| Olympus America INC. | $19.32 | 2021 | |
| Novo Nordisk INC | $18.67 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $14.59 | 2025 | Sutab, Suflave |
| Celltrion USA INC. | $14.37 | 2025 | Vegzelma |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,307.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Dwivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.